366 related articles for article (PubMed ID: 11899096)
1. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy.
Blask DE; Sauer LA; Dauchy RT
Curr Top Med Chem; 2002 Feb; 2(2):113-32. PubMed ID: 11899096
[TBL] [Abstract][Full Text] [Related]
2. Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events.
Blask DE; Sauer LA; Dauchy RT; Holowachuk EW; Ruhoff MS; Kopff HS
Cancer Res; 1999 Sep; 59(18):4693-701. PubMed ID: 10493527
[TBL] [Abstract][Full Text] [Related]
3. Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal.
Blask DE; Dauchy RT; Sauer LA
Endocrine; 2005 Jul; 27(2):179-88. PubMed ID: 16217131
[TBL] [Abstract][Full Text] [Related]
4. Circadian stage-dependent inhibition of human breast cancer metabolism and growth by the nocturnal melatonin signal: consequences of its disruption by light at night in rats and women.
Blask DE; Dauchy RT; Brainard GC; Hanifin JP
Integr Cancer Ther; 2009 Dec; 8(4):347-53. PubMed ID: 20042410
[TBL] [Abstract][Full Text] [Related]
5. Antineoplastic effects of melatonin on a rare malignancy of mesenchymal origin: melatonin receptor-mediated inhibition of signal transduction, linoleic acid metabolism and growth in tissue-isolated human leiomyosarcoma xenografts.
Dauchy RT; Blask DE; Dauchy EM; Davidson LK; Tirrell PC; Greene MW; Tirrell RP; Hill CR; Sauer LA
J Pineal Res; 2009 Aug; 47(1):32-42. PubMed ID: 19486272
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic actions of melatonin in cancer: possible mechanisms.
Srinivasan V; Spence DW; Pandi-Perumal SR; Trakht I; Cardinali DP
Integr Cancer Ther; 2008 Sep; 7(3):189-203. PubMed ID: 18815150
[TBL] [Abstract][Full Text] [Related]
7. Circadian regulation of molecular, dietary, and metabolic signaling mechanisms of human breast cancer growth by the nocturnal melatonin signal and the consequences of its disruption by light at night.
Blask DE; Hill SM; Dauchy RT; Xiang S; Yuan L; Duplessis T; Mao L; Dauchy E; Sauer LA
J Pineal Res; 2011 Oct; 51(3):259-69. PubMed ID: 21605163
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of melatonin anticancer effects.
Hill SM; Frasch T; Xiang S; Yuan L; Duplessis T; Mao L
Integr Cancer Ther; 2009 Dec; 8(4):337-46. PubMed ID: 20050373
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic targets of cancer drugs: Modulation by melatonin.
Moloudizargari M; Moradkhani F; Hekmatirad S; Fallah M; Asghari MH; Reiter RJ
Life Sci; 2021 Feb; 267():118934. PubMed ID: 33385405
[TBL] [Abstract][Full Text] [Related]
10. The validity of melatonin as an oncostatic agent.
Panzer A; Viljoen M
J Pineal Res; 1997 May; 22(4):184-202. PubMed ID: 9247204
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of fatty acid transport and proliferative activity in tissue-isolated human squamous cell cancer xenografts perfused in situ with melatonin or eicosapentaenoic or conjugated linoleic acids.
Dauchy RT; Dauchy EM; Davidson LK; Krause JA; Lynch DT; Tirrell PC; Tirrell RP; Sauer LA; Van der Riet P; Blask DE
Comp Med; 2007 Aug; 57(4):377-82. PubMed ID: 17803052
[TBL] [Abstract][Full Text] [Related]
12. Melatonin enhances junctional transfer in normal C3H/10T1/2 cells.
Ubeda A; Trillo MA; House DE; Blackman CF
Cancer Lett; 1995 May; 91(2):241-5. PubMed ID: 7767915
[TBL] [Abstract][Full Text] [Related]
13. Modulation of intracellular calcium and calmodulin by melatonin in MCF-7 human breast cancer cells.
Dai J; Inscho EW; Yuan L; Hill SM
J Pineal Res; 2002 Mar; 32(2):112-9. PubMed ID: 12071468
[TBL] [Abstract][Full Text] [Related]
14. New actions of melatonin on tumor metabolism and growth.
Blask DE; Sauer LA; Dauchy R; Holowachuk EW; Ruhoff MS
Biol Signals Recept; 1999; 8(1-2):49-55. PubMed ID: 10085462
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor transactivation in MCF-7 breast cancer cells by melatonin and growth factors.
Ram PT; Kiefer T; Silverman M; Song Y; Brown GM; Hill SM
Mol Cell Endocrinol; 1998 Jun; 141(1-2):53-64. PubMed ID: 9723886
[TBL] [Abstract][Full Text] [Related]
16. Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions.
Cos S; González A; Martínez-Campa C; Mediavilla MD; Alonso-González C; Sánchez-Barceló EJ
Cancer Detect Prev; 2006; 30(2):118-28. PubMed ID: 16647824
[TBL] [Abstract][Full Text] [Related]
17. Melatonin uptake and growth prevention in rat hepatoma 7288CTC in response to dietary melatonin: melatonin receptor-mediated inhibition of tumor linoleic acid metabolism to the growth signaling molecule 13-hydroxyoctadecadienoic acid and the potential role of phytomelatonin.
Blask DE; Dauchy RT; Sauer LA; Krause JA
Carcinogenesis; 2004 Jun; 25(6):951-60. PubMed ID: 14754876
[TBL] [Abstract][Full Text] [Related]
18. Does the use of melatonin overcome drug resistance in cancer chemotherapy?
Asghari MH; Ghobadi E; Moloudizargari M; Fallah M; Abdollahi M
Life Sci; 2018 Mar; 196():143-155. PubMed ID: 29374563
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of ERK1/2 Signaling Pathway is Involved in Melatonin's Antiproliferative Effect on Human MG-63 Osteosarcoma Cells.
Liu L; Xu Y; Reiter RJ; Pan Y; Chen D; Liu Y; Pu X; Jiang L; Li Z
Cell Physiol Biochem; 2016; 39(6):2297-2307. PubMed ID: 27832629
[TBL] [Abstract][Full Text] [Related]
20. ELF magnetic fields, breast cancer, and melatonin: 60 Hz fields block melatonin's oncostatic action on ER+ breast cancer cell proliferation.
Liburdy RP; Sloma TR; Sokolic R; Yaswen P
J Pineal Res; 1993 Mar; 14(2):89-97. PubMed ID: 8320637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
